OAC0205	Integration of PrEP services and assisted partner notification into an STI Clinic in Lilongwe, Malawi	Oral abstract session with live Q&A	HIV prevention research
OAC0303	The effect of primary health care on AIDS: a cohort study of 3.4 million individuals in Brazil	Oral abstract session with live Q&A	HIV prevention research
OAC0304	Initiation of pre-exposure prophylaxis (PrEP) among key populations in PEPFAR-supported countries during 2019–2022	Oral abstract session with live Q&A	HIV prevention research
OAC0305	Increased HIV prevention coverage among Australian gay and bisexual men with regular partners: results of national behavioural surveillance, 2018-22	Oral abstract session with live Q&A	HIV prevention research
OAC0402	No association between in-utero PrEP exposure and bone mineral density at 36 months of age among mother-infant pairs in Kenya	Oral abstract session with live Q&A	HIV prevention research
OAC0404	Drug-drug interaction between emtricitabine/tenofovir alafenamide (FTC/TAF)-based PrEP and feminizing hormones in transgender women: peripheral blood mononuclear cells and urine analysis from the iFACT3 study	Oral abstract session with live Q&A	HIV prevention research
OAC0502	A pharmacist-led oral PrEP refill visit with client HIV self-testing significantly improved continuation in Kenya	Oral abstract session with live Q&A	HIV prevention research
OAC0505	Increased use of event-driven PrEP during COVID-19 in Australia: results from behavioural surveillance 2019-2021	Oral abstract session with live Q&A	HIV prevention research
OALBX0203	Initial PrEP product choice: results from the HPTN 084 open-label extension	Oral abstract session with live Q&A	HIV prevention research
OALBX0204	Racial disparities in HIV incidence and PrEP non-adherence among gay and other men who have sex with men (MSM) and transgender women (TGW) using oral PrEP in Brazil: ImPrEP Study	Oral abstract session with live Q&A	HIV prevention research